Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Locally advanced or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC)~* ECOG performance status 0-3~* Treatment phase: histologically confirmed EGFR exon 19 deletion or exon 21 mutation in the diagnostic phase of the study~* Adequate haematological, liver and renal function~* Female patients must be postmenopausal, surgically sterile, or agree to use a barrier method of contraception~* Male patients must be surgically sterile or agree to use a barrier method of contraception~Exclusion Criteria:~* Previous treatment for NSCLC with chemotherapy or therapy against EGFR, either with antibody or small molecule (tyrosine kinase inhibitor)~* Symptomatic cerebral metastases~* Pregnant or lactating women~* Any other concomitant anti-cancer therapy (until disease progression and discontinuation of Tarceva therapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).